Birchview Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Birchview Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,503	Closed	-$41K	–	87
2026 Q1	$41K	Buy	17,503 +503	+3%	+$1.3K	0.02%	71
2025 Q4	$22.9K	Hold	17,000	–	–	0.01%	68
2025 Q3	$25.7K	Hold	17,000	–	–	0.02%	69
2025 Q2	$19.7K	Hold	17,000	–	–	0.02%	70
2025 Q1	$27K	Hold	17,000	–	–	0.02%	68
2024 Q4	$51.5K	Buy	17,000 +1,000	+6%	+$3.28K	0.04%	66
2024 Q3	$58.9K	Hold	16,000	–	–	0.05%	58
2024 Q2	$65.4K	Hold	16,000	–	–	0.06%	58
2024 Q1	$252K	Hold	16,000	–	–	0.21%	49
2023 Q4	$242K	Buy	+16,000	New	+$233K	0.19%	47
2022 Q3	–	Sell	-8,000	Closed	-$225K	–	61
2022 Q2	$225K	Hold	8,000	–	–	0.16%	49
2022 Q1	$369K	Hold	8,000	–	–	0.27%	45
2021 Q4	$672K	Hold	8,000	–	–	0.43%	38
2021 Q3	$533K	Hold	8,000	–	–	0.36%	39
2021 Q2	$426K	Buy	+8,000	New	+$428K	0.25%	46

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Birchview Capital's ZNTL Position: Q2 2026 in Review

Birchview Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 17,503 shares — an estimated $41K sold.

Birchview Capital first reported a position in ZNTL in Q2 2021 and held it in 15 quarters. The position peaked at $672K in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Birchview Capital reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Birchview Capital sold 17,503 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $41K.
Birchview Capital first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 15 quarters.
Birchview Capital's Zentalis Pharmaceuticals position peaked at $672K in Q4 2021.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.